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Abstract
Background: Timely risk stratification is the key strategy to improve prognosis of patients with sepsis. Previous
study has proposed to develop a powerful risk assessment rule by the combination of Acute Physiology and
Chronic Health Evaluation II (APACHE II) score and plasma soluble urokinase plasminogen activator receptor
(suPAR). That reaffirmation of suPAR as a prognostic marker in Chinese patients with severe sepsis is the aim of the
study.
Methods: A total of 137 consecutive Chinese patients with sepsis were enrolled in a prospective study cohort.
Demographic and clinical characteristics, conventional risk factors and important laboratory data were prospectively
recorded. Sequential plasma suPAR concentrations were measured by an enzymeimmunoabsorbent assay on days
1, 3, and 7 after admission to the intensive care unit (ICU). Receiver operating characteristic (ROC) curves and Cox
regression analysis were used to examine the performance of suPAR in developing a rule for risk stratification.
Results: The results showed that plasma suPAR concentrations remained relatively stable within survivors and
non-survivors during the first week of disease course. Regression analysis indicated that APACHE II ≥15 and suPAR
≥10.82 ng/mL were independently associated with unfavorable outcome. With the above cutoffs of APACHE II and
suPAR, strata of disease severity were determined. The mortality of each stratum differed significantly from the
others.
Conclusions: Combination of APACHE II score and suPAR may supply the powerful prognostic utility for the
mortality of sepsis.
Keywords: Sepsis, Risk stratification, Soluble urokinase plasminogen activator receptor (suPAR), Acute Physiology
and Chronic Health Evaluation II (APACHE II)
Background
The incidence of sepsis in adults has been increasing,
with severe sepsis and septic shock remaining among
the major causes of death worldwide [1]. Despite the
mortality is on a declining trend in recent years [2], low
awareness, late recognition, and improper treatment are
still common [3].
One of the fundamental principles for the appropriate
management of sepsis is timely discrimination of the pa-
tients at high risk for death [4]. This is generally
dependent on the application of score systems and
plasma biomarkers. Although the well-recognized score
is the Acute Physiology and Chronic Health Evaluation
II (APACHE II), APACHE II score has some potential
pitfalls that may lead to inaccurate evaluation. Take
young patients with severe sepsis but without chronic
organ dysfunction for instance, the APACHE II score
may be relatively low despite the risk for an unfavorable
outcome is high [5].
Although various biological markers are widely ex-
plored [6–9], only a few have been applied in the clinical
practice. The soluble urokinase plasminogen activator
receptor (suPAR), which exists in three forms (I-III, II-
III and I), is regarded as a novel biomarker of immune
system activation [10]. Urokinase plasminogen activator
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receptor (uPAR) is embedded in the cell membranes of
various immunologically active cells and, with its ligand,
urokinase plasminogen activator (uPA), takes part in a
range of immunologic activities [11]. Upon inflammatory
stimulation, uPAR is cleaved from the cell surface by
proteases into the soluble form of the receptor-suPAR-
which can be assessed in blood, urine, bronchoalveolar
lavage, and cerebrospinal fluid [12, 13]. Recent studies
have revealed that suPAR may have the ability to predict
the mortality of sepsis [14–17]. It is noteworthy that
Giamarellos-Bourboulis et al. have proposed a new prog-
nostication rule for predicting the outcome of sepsis by
APACHE II score and suPAR [5].
The primary purpose of the present study was to fur-
ther reaffirm the prediction rule for the mortality in
Chinese patients with sepsis by combining APACHE II
score and plasma suPAR concentrations.
Methods
Study design
This prospective trial involved consecutive Chinese pa-
tients with sepsis presenting to the intensive care unit
(ICU) of the Department of Emergency, Xinhua Hos-
pital, Shanghai Jiaotong University School of Medicine,
from March 2013 to February 2015.
For each patient with suspected infection, a complete
diagnostic work-up was performed. The work-up com-
prised demographic and clinical characteristics, conven-
tional risk factors, and important laboratory data
including blood routine examination, microbiological
culturing, chest x-ray, and chest or abdominal computed
tomography if necessary. Broad spectrum antimicrobial
treatment was used within 1 h from the recognition of
the septic status.
Patients were eligible if they met the inclusion criteria:
(1) age of at least 18 years; (2) sepsis due to one of the
following infections: community acquired pneumonia,
hospital acquired pneumonia, ventilator-associated
pneumonia, acute pyelonephritis, intra-abdominal infec-
tion, or primary bacteremia; and (3) blood sampling
within 24 h from the presentation of signs of sepsis. Pa-
tients affected by advanced cancer or terminal patients
with other pathologies were excluded.
All eligible patients were further classified according
to standard definitions of sepsis, severe sepsis, and
septic shock [18]. More specifically, sepsis was defined
as the presence of suspected or confirmed infection
together with two or more criteria for a systemic
inflammatory response; severe sepsis was defined as
sepsis with sepsis-induced organ dysfunction,
hypotension or hypoperfusion; septic shock was de-
fined as refractory hypotension or hypoperfusion des-
pite sufficient fluid resuscitation.
Blood measurements
Venous blood (3 mL) was collected from patients pre-
senting to the ICU (day 1) and repeated on the following
day 3 and day 7 after admission. Whole blood was
drawn into a centrifuge tube containing EDTA anti-
coagulant. After centrifugation at 3,000 g for 10 min at
4 °C, plasma samples were kept frozen at −80 °C until
assayed. suPAR was determined in duplicate by a com-
mercial double monoclonal antibody sandwich enzyme
immunoassay (suPARnostic® Standard kit; ViroGates A/
S, Birkerød, Denmark) in accordance with the
instructions of the manufacturer. Every 45 blood sam-
ples can be measured within about 4 h. The linearity of
this assay is comprised between 2.0 and 15.6 ng/mL, and
the total imprecision, expressed as coefficient of vari-
ation (CV %), ranges from 2.3 to 6.0 %.
Study outcomes
Patients who survived were further followed up by tele-
phone calls. The unfavorable outcome of the study was
defined as death from any cause within 28 days after ad-
mission to the ICU.
Statistical analysis
Continuous variables were presented as mean values ±
standard deviation (SD) or median with interquartile ranges
(IQR), while categorical variables were expressed as per-
centages. The statistical significance of intergroup differ-
ences was compared through unpaired Student’s t-test or
Mann–Whitney U test for continuous variables and
through Pearson’s χ2 test for categorical variables.
The following steps were performed to establish a risk
stratification rule: First, receiver operating characteristic
(ROC) analysis was conducted with baseline levels of
APACHE II score and suPAR to determine the predic-
tion sensitivity and specificity of the variables. Second,
we used univariate and multivariate Cox regression ana-
lyses to calculate hazard ratios (HR) with 95 % confi-
dence intervals (CIs). Third, strata of disease severity
were established using the cutoffs of APACHE II score
and suPAR. Odds ratios (OR) and 95 % CIs for risk pre-
diction within each stratum were assessed using Mantel
and Haenszel statistics. Fourth, mortalities between
strata were estimated using the log-rank test.
A two-sided P value < 0.05 was considered statisti-
cally significant. All analyses were performed by the
IBM SPSS Statistics software version 19.0 (SPSS, Chi-
cago, IL, USA).
Results
Baseline characteristics of the study population
A total of 137 consecutive patients (51.09 % men; mean
age, 69.53 ± 9.28 years) were eligible for enrollment in
the study. After the initial evaluation performed in the
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ICU, patients were divided into three groups accord-
ing the disease severity: group 1, patients with sepsis
(n = 56); group 2, those with severe sepsis (n = 49);
and group 3, those with septic shock (n = 32). The
baseline clinical and laboratory characteristics of the
patients are elaborated in Table 1. The most common
locations of infection were lung and urinary tract,
and the distribution of locations was similar among
the three groups. The commonest isolated pathogens
from the study cohort were Gram-negative microor-
ganisms with a predominance of Escherichia coli, and
blood cultures were positive in 43.80 % of all patients.
There was not any difference in pathogen strains
among the different groups (Table 1).
There were no significantly statistical differences in pa-
tients with sepsis compared to those in severe sepsis or
septic shock for gender or age. Patients with severe sep-
sis or septic shock tended to have higher baseline levels
Table 1 Baseline clinical and laboratory characteristics of the study subjects
Patient group
Characteristics Sepsis Severe sepsis Septic shock P value
Demographics and underlying conditions
Number of patients 56 49 32 -
Males, no. (%) 29(51.79 %) 27(55.10 %) 14(43.75 %) 0.418
Age (years), mean ± SD
COPD, no (%)
Hypertension, no (%)



































































































































































Abbreviations: COPD chronic obstructive pulmonary disorder, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA sequential organ failure
assessment, suPAR soluble urokinase plasminogen activator receptor, PCT procalcitonin, BUN blood urea nitrogen, Scr serum creatinine, ALT alanine transaminase,
AST aspartate transaminase, CRRT continuous renal replacement therapy
Data are expressed as no. (%), or mean (standard deviation, SD) as appropriate
Significant differences are marked by *(P < 0.05) or **(P < 0.01)
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of APACHE II score, Sequential Organ Failure Assess-
ment (SOFA) score, suPAR, procalcitonin (PCT) and
lactic acid compared with patients with sepsis. In
addition, there were 19 patients (13.87 %) receiving
mechanical ventilation treatment, 23 patients (16.79 %)
receiving continuous renal replacement therapy, and 17
patients (12.41 %) receiving vasopressor support. There
were significant differences in the proportion of patients
receiving mechanical ventilation, continuous renal re-
placement therapy or vasopressor support among the
three groups (Table 1).
Kinetics of suPAR
Among the enrolled patients, a total of 117 patients sur-
vived and 20 died. As shown in Fig. 1a, patients who
died had significantly higher suPAR concentrations
(15.82 ± 2.72 ng/mL) on admission in comparison with
the survivors (9.04 ± 3.41 ng/mL, P < 0.01). To investi-
gate whether plasma suPAR concentrations remain con-
stant over time, serial plasma determinations were
further conducted on day 3 and day 7 after admission.
At each indicated day of sampling, plasma suPAR con-
centrations were markedly higher among non-survivors
than among survivors. Plasma suPAR concentrations
remained stable separately within survivors and within
non-survivors during the first week of the disease
course. In addition, in the septic shock group 14 patients
died and 18 survived. These non-survivors had signifi-
cantly higher suPAR concentrations (17.05 ± 2.96 ng/
mL) on admission when compared with the survivors
(10.48 ± 1.86 ng/mL, P < 0.01) in the septic shock group
(Fig. 1b).
Value of indicators in predicting poor outcome
ROC analysis was constructed to examine the perform-
ance of indicators as predictors of poor outcome, and
the area under the curve (AUC) for each indicator was
calculated, respectively. The AUC, optimal cutoff value,
sensitivity and specificity of each indicator are presented
in Table 2. ROC curves indicated that suPAR had a
strong power for predicting unfavorable outcome as sug-
gested by AUC of 0.788 ± 0.058, which was less than that
of APACHE II score (0.813 ± 0.055, P < 0.05) but greater
than that of SOFA score (0.779 ± 0.075, P < 0.05) and
PCT (0.651 ± 0.081, P < 0.01) (Fig. 2). Coordinate points
of ROCs indicated that an APACHE II score of at least
15 as a cutoff had a specificity of greater than 70 % to
predict death and suPAR of at least 10.82 ng/mL showed
a specificity of greater than 70 % to predict death.
Furthermore, ROC analysis of the combination of
APACHE II score and suPAR was further performed.
We found that the AUCs were greater for the combin-
ation of APACHE II score and suPAR (0.878 ± 0.042)
than for the single APACHE II score or single suPAR
(Fig. 3), demonstrating that combination of APACHE II
score and suPAR may supply the more powerful prog-
nostic utility for the mortality of sepsis.
Univariate Cox regression analysis
We performed univariate Cox regression analysis to
examine the associations of each variable with unfavor-
able outcome and calculated the standardized regression
coefficient (β) and the HR for each variable. As shown in
Table 3, baseline APACHE II score had the greatest ab-
solute value of standardized β value (0.2457). The abso-
lute value of standardized β value for suPAR was 0.1482
and the unadjusted HR was 2.18 (95 % confidence inter-
val [CI], 1.77-2.95, P = 0.000), indicating that suPAR had
a power for predicting unfavorable outcome.
Multivariate Cox regression analysis
A multivariate Cox regression analysis was conducted
using a forward step-wise manner to determine a novel
risk stratification rule. All the observed baseline parame-
ters like age, gender, lactic acid, blood urea nitrogen,
serum creatinine, APACHE II score, SOFA score, suPAR
Fig. 1 Plasma suPAR concentrations among survivors and non-survivors during the course of 7 days. a Plasma suPAR concentrations among 117
survivors and 20 non-survivors from all the patients. b Plasma suPAR concentrations among 18 survivors and 14 non-survivors from the patients
with septic shock. Values are expressed as mean ± SD. **P < 0.01 between survivors and non-survivors at the indicated day of sampling. suPAR,
soluble urokinase plasminogen activator receptor
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and PCT were included in the prediction model when ad-
vent of death was set as the dependent variable. The re-
sults are shown in Table 4. According to this analysis,
APACHE II score of at least 15 and plasma suPAR con-
centrations of at least 10.82 ng/mL were the independent
predictors which entered the equation, demonstrating that
these above defined cutoff values may be safely used to
create a stratification rule for evaluating unfavorable out-
come in sepsis.
The prognostic significance of suPAR was further
confirmed after the risk stratification rule was gener-
ated (Table 5). More precisely, OR for death with
suPAR of at least 10.82 ng/mL among patients with
an APACHE II score of less than 15 was 4.72; OR
was 2.04 with suPAR of at least 10.82 ng/mL among
patients with an APACHE II score of at least 15. The
calculated ORs were significantly different, demon-
strating that APACHE II score and suPAR were inde-
pendently associated with the unfavorable outcome
and could both be integrated into a risk stratification
rule.
Risk stratification rule of APACHE II score and suPAR
On the basis of the above cutoffs of APACHE II score
and suPAR, risk stratification rule was determined as fol-
lows: (A) patients with an APACHE II score of less than
15 and suPAR of less than 10.82 ng/mL, (B) patients
with an APACHE II score of less than 15 and suPAR of
at least 10.82 ng/mL, (C) patients with an APACHE II
score of at least 15 and suPAR of less than 10.82 ng/mL,
and (D) patients with an APACHE II score of at least 15
and suPAR of at least 10.82 ng/mL. There were 72, 27,
18, and 20 patients in each stratum, with respective mor-
talities of 1.39 % (n = 1), 11.11 % (n = 3), 27.78 % (n = 5),
and 55.0 % (n = 11). As show in Fig. 4, each stratum dif-
fered significantly from the others (P = 0.002 by the log-
rank test within the defined strata). This prediction score
corresponded to different grades of disease severity,
Table 2 Performance of variables in predicting unfavorable outcome
Variables AUC ROC P value Cutoff value Sensitivity (%) Specificity (%)










suPAR 0.788 ± 0.058 <0.001** ≥10.82 84.9 77.6
PCT 0.651 ± 0.081 0.078 ≥24.97 57.5 69.2
Abbreviations: AUC ROC area under the receiver operating characteristic curve, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA sequential
organ failure assessment, suPAR soluble urokinase plasminogen activator receptor, PCT procalcitonin
Significant differences are marked by **(P < 0.01)
Fig. 2 Receiver operating characteristic (ROC) curves of suPAR, PCT, APACHE II score, and SOFA score on day 1. suPAR had a strong power for
predicting unfavorable outcome as suggested by area under the curve (AUC) of 0.788 ± 0.058, P = 0.001. suPAR, soluble urokinase plasminogen
activator receptor; PCT, procalcitonin; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ Failure Assessment
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therefore patients with severe sepsis/septic shock tended
to have score levels (C) and (D) when patients with
sepsis tended to have score levels (A) and (B).
Discussion
Undoubtedly, APACHE II score has been advocated as
the gold standard for risk evaluation in critically ill pa-
tients [19]. Nevertheless, a growing body of evidence has
suggested that the score may supply inaccurate informa-
tion in the certain patients, such as disproportionately
high scores in patients who are loss of consciousness
[20]. This translates into a real-world context in which
the efficacy of APACHE II score to predict death is not
as powerful as clinicians would consider.
To our knowledge, previous study conducted by
Giamarellos-Bourboulis et al. has proposed a new prog-
nostication rule for predicting the outcome of sepsis by
APACHE II score and suPAR [5]. Our study was to fur-
ther reaffirm the risk stratification system for Chinese
patients with sepsis by combining APACHE II score and
plasma suPAR concentrations. There were some differ-
ences between our study and Giamarellos-Bourboulis’s
study. First, the enrolled patients of the two studies were
from different ethnic groups. We enrolled Asian popula-
tions (Chinese origin), while Giamarellos-Bourboulis et
al. mainly enrolled the European populations. Second,
the cutoffs of APACHE II and suPAR which were used
to determine the strata of disease severity were not uni-
formly the same. Specifically, our study indicated that
Fig. 3 Receiver operating characteristic (ROC) curves of suPAR, APACHE II score, and their combination on day 1. The combination of suPAR and
APACHE II score had a strong power for predicting unfavorable outcome as suggested by area under the curve (AUC) of 0.878 ± 0.042, P = 0.000.
suPAR, soluble urokinase plasminogen activator receptor; APACHE II, Acute Physiology and Chronic Health Evaluation II
Table 3 Predictors of unfavorable outcome by univariate Cox
regression analysis














































Abbreviations: BUN blood urea nitrogen, Scr serum creatinine, APACHE II Acute
Physiology and Chronic Health Evaluation II, SOFA sequential organ failure
assessment, suPAR soluble urokinase plasminogen activator receptor, PCT
procalcitonin, CI confidence interval
The hazard ratio indicates the risk of obtaining unfavorable outcome
Significant differences are marked by *(P < 0.05) or **(P < 0.01)
Table 4 Independent predictors of unfavorable outcome by
multivariate Cox regression analysis
Variables Standard β Hazard ratio 95 % CI P value
APACHE II score 0.2743 3.57 2.38–4.40 <0.001**
SuPAR 0.1530 2.26 1.94–2.87 <0.001**
Abbreviations: APACHE II Acute Physiology and Chronic Health Evaluation II,
suPAR soluble urokinase plasminogen activator receptor, CI confidence interval
The hazard ratio indicates the risk of obtaining unfavorable outcome
Significant differences are marked by **(P < 0.01)
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APACHE II ≥15 and suPAR ≥10.82 ng/mL were inde-
pendently associated with unfavorable outcome while
Giamarellos-Bourboulis’s study showed that APACHE II
≥17 and suPAR ≥12 ng/ml were the optimal cutoffs.
Third, we constructed ROC analysis and calculated the
AUC to compare the performance of suPAR, PCT, APA-
CHE II score, and SOFA score as predictors of poor out-
come. We found that suPAR had a strong power for
predicting unfavorable outcome as suggested by AUC of
0.788 ± 0.058, which was less than that of APACHE II
score (0.813 ± 0.055) but greater than that of SOFA score
(0.779 ± 0.075) and PCT (0.651 ± 0.081). However,
Giamarellos-Bourboulis et al. just conducted ROC ana-
lysis with suPAR and APACHE II score as independent
variables to predict unfavorable outcome. Taken to-
gether, given enrolled patients were from different ethnic
groups, our study may further confirm the preliminary
conclusion that a prediction rule with four levels of risk
in sepsis based on APACHE II score and suPAR was
proposed.
Similar to the findings of a previous clinical trial con-
cerning plasma suPAR measurement [15], our study
clearly showed that suPAR concentrations were relatively
stable in the systemic circulation in both survivors and
non-survivors during the first week of the disease
course. Therefore, we infer that the validity of the
developed prognostication score remains constant even
if suPAR is not measured during the very first days after
ICU admission due to the stability of suPAR concentra-
tions over the disease course. These findings were com-
parable to other diseases including chronic obstructive
pulmonary disease (COPD) [21] or acute respiratory dis-
tress syndrome (ARDS) [22], in which suPAR was
regarded as an independent predictor for unfavorable
outcomes.
Severe sepsis has a reported annual incidence in adults
of up to 300 cases per 100,000 population [23, 24]. Af-
fected patients have high mortalities, complications, and
resource utilization. Although figures have improved in
the recent years [2, 3], the risk for death remains high
[25]. Consequently, improving outcome may be a daunt-
ing work. One of pivotal measures is to identify the sep-
tic patients with poor prognosis rapidly [4]. Our study
suggested one composite rule for determining patients
with sepsis at high risk on the basis of APACHE II score
and plasma suPAR concentrations. Actually, the meas-
urement procedure is so simple that we can complete
the measurement for every 45 patient samples within
about 4 h. The price for the measurement is also rela-
tively reasonable and we only spend 6,000 CNY (about
924 USD) on evaluating 45 patient samples, that means
we need spend about 133 CNY (20 USD) on measuring
Table 5 Validation of the novel stratification rule
APACHEII score suPAR Survivors, Number (%) Non-survivors, Number (%) P value OR (95 % CI)
<15 <10.82 71(98.61 %) 1(1.39 %) <0.001** 4.72 (3.36–5.81)
≥10.82 24(88.89 %) 3(11.11 %)
≥15 <10.82 13(72.22 %) 5(27.78 %) <0.001** 2.04 (1.85–3.50)
≥10.82 9(45.00 %) 11(55.00 %)
Abbreviations: APACHE II Acute Physiology and Chronic Health Evaluation II, suPAR soluble urokinase plasminogen activator receptor, OR odds ratio, CI
confidence interval
The OR indicates the risk of obtaining unfavorable outcome
Significant differences are marked by **(P < 0.01)
Fig. 4 Kaplan-Meier estimates of survival of patients stratified into four strata of severity. Every stratum differed significantly from the others.
P = 0.002 by the log-rank test within the four defined strata. APACHE II, Acute Physiology and Chronic Health Evaluation II; suPAR, soluble
urokinase plasminogen activator receptor
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one patient sample. Undoubtedly, the suPAR measure-
ment is relatively cost-effective. Therefore, given the
simple and inexpensive measurement, the combination
of APACHE II score and plasma suPAR concentrations
may contribute to intensive care management in the
septic patients properly.
Currently, evidence has suggested that the value of
single scoring system as a standard of clinical decision-
making in septic patients is questionable. APACHE II
score is likely to recognize either low-risk patients or
very-high-risk patients, but not these patients between
the two extremes [20]. The proposed risk stratification
rule fulfills this need because it discriminates not only
patients lying at one of the two extremes - strata (A)
and (D) - but also patients with moderate disease sever-
ity, namely patients with an APACHE II score of less
than 15 and suPAR of at least 10.82 ng/mL or patients
with an APACHE II score of at least 15 and suPAR of
less than 10.82 ng/mL, who belong to strata (B) and (C),
respectively.
Conclusions
In summary, combination of APACHE II score and
suPAR may supply the powerful prognostic utility for
the mortality of sepsis. Our findings suggest that incorp-
orating suPAR into APACHE II score as a composite
risk stratification rule for sepsis is worth considering.
Abbreviations
APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, acute
respiratory distress syndrome; AUC, area under the curve; CI, confidence
interval; COPD, chronic obstructive pulmonary disease; ICU, intensive care
unit; IQR, interquartile ranges; OR, odds ratio; PCT, procalcitonin; ROC,
receiver operating characteristic; SD, standard deviation; SOFA, sequential
organ failure assessment; suPAR, soluble urokinase plasminogen activator
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